Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KEMPER CorpKMPR · Entity 719 | Director | August 10, 2026 | August 11, 2026 |
| Teladoc Health, Inc.TDOC · Entity 1547 | Director · CHIEF EXECUTIVE OFFICER | March 19, 2024 | March 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KEMPER Corp
Report date August 10, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,802 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Purchase · Acquired 5,000 · Balance 31,802 |
Teladoc Health, Inc.
Report date March 19, 2024 · Filed March 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 197,728 |
Reported balance
After 2024-03-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-19 · Grant · Acquired 197,728 · Balance 197,728 F1: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2: One-third of the restricted stock units vest on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.
F2: One-third of the restricted stock units vest on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2022 Filed May 5, 2022 15:34 UTC | KEMPER Corp KMPR · Entity 719 | GrantCommon Stock | 2,525 | $0.00 | $0.00 |
DisclosureSEC source: 0000860748-22-000090 · wf-form4_165176486262242.xml · nonDerivative · entry 1 GOREVIC JASON N · CIK 0001208500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,139 F1 · shares: Award of restricted stock units based on a grant date value of $130,000 under the Kemper Corporation 2020 Omnibus Equity Plan ("Plan"), subject to forfeiture and other restrictions until vested pursuant to the Plan and the award agreement. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionPerformance Stock Units · Derivative | 21,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002053 · edgar.xml · derivative · entry 5 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Performance stock units convert to shares of TDOC common stock on a one-for-one basis. F5 · derivative.exercise_date: On February 26, 2020, the reporting person earned 65,435 performance stock units, vesting in three substantially equal annual installments beginning on March 4, 2020. F5 · derivative.expiration_date: On February 26, 2020, the reporting person earned 65,435 performance stock units, vesting in three substantially equal annual installments beginning on March 4, 2020. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 16,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002053 · edgar.xml · derivative · entry 4 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. F4 · derivative.exercise_date: On March 4, 2019, the reporting person was granted 50,333 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 4, 2019, the reporting person was granted 50,333 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 21,812 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-002053 · edgar.xml · nonDerivative · entry 2 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Performance stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 16,778 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-002053 · edgar.xml · nonDerivative · entry 1 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:38 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionPerformance Stock Units · Derivative | 5,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002568 · form4-03042022_020334.xml · derivative · entry 13 GOREVIC JASON N · CIK 0001208500 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,564 Underlying: Common Stock · 5,782 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Performance stock units convert to shares of TDOC common stock on a one-for-one basis. F13 · derivative.exercise_date: On March 2, 2022, the reporting person earned 17,346 performance stock units, vesting in three substantially equal annual installments beginning on March 2, 2022. F13 · derivative.expiration_date: On March 2, 2022, the reporting person earned 17,346 performance stock units, vesting in three substantially equal annual installments beginning on March 2, 2022. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:38 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GrantPerformance Stock Units · Derivative | 17,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002568 · form4-03042022_020334.xml · derivative · entry 12 GOREVIC JASON N · CIK 0001208500 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,346 Underlying: Common Stock · 17,346 shares Expires not disclosed F6 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of TDOC common stock. F11 · shares: Performance award amount determined based on metrics in respect of the issuer's 2021 financial results F12 · derivative.exercise_date: The performance stock units vest in three substantially equal annual installments beginning on March 2, 2022. F12 · derivative.expiration_date: The performance stock units vest in three substantially equal annual installments beginning on March 2, 2022. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:38 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 7,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002568 · form4-03042022_020334.xml · derivative · entry 11 GOREVIC JASON N · CIK 0001208500 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,296 Underlying: Common Stock · 7,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. F10 · derivative.exercise_date: On March 2, 2021, the reporting person was granted 22,944 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date. F10 · derivative.expiration_date: On March 2, 2021, the reporting person was granted 22,944 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:38 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionPerformance Stock Units · Derivative | 3,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002568 · form4-03042022_020334.xml · derivative · entry 10 GOREVIC JASON N · CIK 0001208500 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,891 Underlying: Common Stock · 3,893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Performance stock units convert to shares of TDOC common stock on a one-for-one basis. F9 · derivative.exercise_date: On March 2, 2022, the reporting person earned 7,784 performance stock units, vesting in two substantially equal annual installments beginning on March 2, 2022. F9 · derivative.expiration_date: On March 2, 2022, the reporting person earned 7,784 performance stock units, vesting in two substantially equal annual installments beginning on March 2, 2022. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:38 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GrantPerformance Stock Units · Derivative | 7,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002568 · form4-03042022_020334.xml · derivative · entry 9 GOREVIC JASON N · CIK 0001208500 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,784 Underlying: Common Stock · 7,784 shares Expires not disclosed F6 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of TDOC common stock. F7 · shares: Performance award amount determined based on metrics in respect of the issuer's financial results over a two-year performance period ending in 2021. F8 · derivative.exercise_date: The performance stock units vest in two substantially equal annual installments beginning on March 2, 2022. F8 · derivative.expiration_date: The performance stock units vest in two substantially equal annual installments beginning on March 2, 2022. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:38 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionPerformance Stock Units · Derivative | 15,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002568 · form4-03042022_020334.xml · derivative · entry 8 GOREVIC JASON N · CIK 0001208500 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,476 Underlying: Common Stock · 15,478 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Performance stock units convert to shares of TDOC common stock on a one-for-one basis. F5 · derivative.exercise_date: On March 2, 2021, the reporting person earned 46,430 performance stock units, vesting in three substantially equal annual installments beginning on March 2, 2021. F5 · derivative.expiration_date: On March 2, 2021, the reporting person earned 46,430 performance stock units, vesting in three substantially equal annual installments beginning on March 2, 2021. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:38 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 9,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002568 · form4-03042022_020334.xml · derivative · entry 7 GOREVIC JASON N · CIK 0001208500 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,104 Underlying: Common Stock · 9,103 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. F4 · derivative.exercise_date: On March 2, 2020, the reporting person was granted 27,311 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 2, 2020, the reporting person was granted 27,311 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:38 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 5,782 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-002568 · form4-03042022_020334.xml · nonDerivative · entry 5 GOREVIC JASON N · CIK 0001208500 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Performance stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:38 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 7,648 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-002568 · form4-03042022_020334.xml · nonDerivative · entry 4 GOREVIC JASON N · CIK 0001208500 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:38 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 3,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-002568 · form4-03042022_020334.xml · nonDerivative · entry 3 GOREVIC JASON N · CIK 0001208500 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Performance stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:38 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 15,478 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-002568 · form4-03042022_020334.xml · nonDerivative · entry 2 GOREVIC JASON N · CIK 0001208500 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Performance stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:38 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 9,103 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-002568 · form4-03042022_020334.xml · nonDerivative · entry 1 GOREVIC JASON N · CIK 0001208500 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:14 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GrantRestricted Stock Units · Derivative | 67,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001901 · edgar.xml · derivative · entry 1 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,376 Underlying: Common Stock · 67,376 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2 · derivative.exercise_date: One-third of the restricted stock units vest on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. F2 · derivative.expiration_date: One-third of the restricted stock units vest on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 16:56 UTC | KEMPER Corp KMPR · Entity 719 | GrantCommon Stock | 614 | $0.00 | $0.00 |
DisclosureSEC source: 0000860748-22-000021 · wf-form4_164390739372451.xml · nonDerivative · entry 1 GOREVIC JASON N · CIK 0001208500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,614 F1 · shares: Award of restricted stock units based on a grant date value of $32,500 under the Kemper Corporation 2020 Omnibus Equity Plan ("Plan"), subject to forfeiture and other restrictions until vested pursuant to the Plan and the award agreement. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 20:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 4,763 | $151.40 | $721,132.49 |
DisclosureSEC source: 0001179110-21-009877 · edgar.xml · nonDerivative · entry 2 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,970 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F3 · price: Represents the weighted average price of transactions ranging from $151.15 to $151.44, inclusive. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 20:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 5,237 | $150.33 | $787,256.74 |
DisclosureSEC source: 0001179110-21-009877 · edgar.xml · nonDerivative · entry 1 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,733 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F2 · price: Represents the weighted average price of transactions ranging from $150.00 to $150.99, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 3 to this Form 4. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 10,000 | $150.12 | $1,501,169.00 |
DisclosureSEC source: 0001179110-21-007943 · edgar.xml · nonDerivative · entry 1 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,970 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 100 | $165.15 | $16,515.00 |
DisclosureSEC source: 0001179110-21-007427 · edgar.xml · nonDerivative · entry 5 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,970 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 1,350 | $164.22 | $221,703.21 |
DisclosureSEC source: 0001179110-21-007427 · edgar.xml · nonDerivative · entry 4 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,070 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F5 · price: Represents the weighted average price of transactions ranging from $163.89 to $164.64, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 3,267 | $163.40 | $533,811.47 |
DisclosureSEC source: 0001179110-21-007427 · edgar.xml · nonDerivative · entry 3 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,420 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F4 · price: Represents the weighted average price of transactions ranging from $162.89 to $163.88, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 4,283 | $162.47 | $695,856.44 |
DisclosureSEC source: 0001179110-21-007427 · edgar.xml · nonDerivative · entry 2 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,687 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F3 · price: Represents the weighted average price of transactions ranging from $161.89 to $162.84, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 1,000 | $161.27 | $161,272.10 |
DisclosureSEC source: 0001179110-21-007427 · edgar.xml · nonDerivative · entry 1 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,970 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F2 · price: Represents the weighted average price of transactions ranging from $160.82 to $161.79, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 5 to this Form 4. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 10,000 | $153.34 | $1,533,400.00 |
DisclosureSEC source: 0001179110-21-006211 · edgar.xml · nonDerivative · entry 1 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,970 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 100 | $160.50 | $16,050.00 |
DisclosureSEC source: 0001179110-21-004948 · edgar.xml · nonDerivative · entry 7 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,970 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 300 | $159.52 | $47,856.99 |
DisclosureSEC source: 0001179110-21-004948 · edgar.xml · nonDerivative · entry 6 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,070 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F7 · price: Represents the weighted average price of transactions ranging from $159.21 to $159.93, inclusive. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 1,047 | $158.30 | $165,743.87 |
DisclosureSEC source: 0001179110-21-004948 · edgar.xml · nonDerivative · entry 5 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,370 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F6 · price: Represents the weighted average price of transactions ranging from $157.93 to $158.84, inclusive. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 3,853 | $156.95 | $604,734.90 |
DisclosureSEC source: 0001179110-21-004948 · edgar.xml · nonDerivative · entry 4 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,417 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F5 · price: Represents the weighted average price of transactions ranging from $156.66 to $157.39, inclusive. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 2,400 | $156.24 | $374,965.92 |
DisclosureSEC source: 0001179110-21-004948 · edgar.xml · nonDerivative · entry 3 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481,270 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F4 · price: Represents the weighted average price of transactions ranging from $155.65 to $156.63, inclusive. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 1,000 | $155.06 | $155,055.00 |
DisclosureSEC source: 0001179110-21-004948 · edgar.xml · nonDerivative · entry 2 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,670 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F3 · price: Represents the weighted average price of transactions ranging from $154.62 to $155.58, inclusive. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 1,300 | $154.12 | $200,354.05 |
DisclosureSEC source: 0001179110-21-004948 · edgar.xml · nonDerivative · entry 1 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,670 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F2 · price: Represents the weighted average price of transactions ranging from $153.59 to $154.58, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7 to this Form 4. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 100 | $184.18 | $18,418.00 |
DisclosureSEC source: 0001179110-21-004326 · edgar.xml · nonDerivative · entry 5 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,970 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 3,790 | $183.42 | $695,159.91 |
DisclosureSEC source: 0001179110-21-004326 · edgar.xml · nonDerivative · entry 4 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,070 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F5 · price: Represents the weighted average price of transactions ranging from $183.10 to $183.94, inclusive. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 10,054 | $182.62 | $1,836,048.41 |
DisclosureSEC source: 0001179110-21-004326 · edgar.xml · nonDerivative · entry 3 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,860 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F4 · price: Represents the weighted average price of transactions ranging from $182.10 to $183.09, inclusive. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 8,056 | $181.55 | $1,462,547.47 |
DisclosureSEC source: 0001179110-21-004326 · edgar.xml · nonDerivative · entry 2 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,914 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F3 · price: Represents the weighted average price of transactions ranging from $181.10 to $182.09, inclusive. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 3,000 | $180.86 | $542,565.90 |
DisclosureSEC source: 0001179110-21-004326 · edgar.xml · nonDerivative · entry 1 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,970 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 4, 2020. F2 · price: Represents the weighted average price of transactions ranging from $180.10 to $181.09, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 5 to this Form 4. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:44 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,484 | $0.00 Strike: $22.30 | $0.00 |
DisclosureSEC source: 0001179110-21-003143 · edgar.xml · derivative · entry 5 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,116 Underlying: Common Stock · 4,484 shares Expires 2027-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 25% of the shares on March 3, 2018. The remainder of the shares vested in 36 equal monthly installments thereafter. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:44 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,190 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001179110-21-003143 · edgar.xml · derivative · entry 4 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,649 Underlying: Common Stock · 8,190 shares Expires 2026-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 25% of the shares on March 7, 2017. The remainder of the shares vested in 36 equal monthly installments thereafter. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:44 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 4,484 | $22.30 | $99,993.20 |
DisclosureSEC source: 0001179110-21-003143 · edgar.xml · nonDerivative · entry 3 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:44 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 8,190 | $12.21 | $99,999.90 |
DisclosureSEC source: 0001179110-21-003143 · edgar.xml · nonDerivative · entry 2 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:44 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 20,220 | $183.18 | $3,703,980.48 |
DisclosureSEC source: 0001179110-21-003143 · edgar.xml · nonDerivative · entry 1 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 548,296 F1 · shares: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock unit and performance stock unit awards. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:15 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionPerformance Stock Units · Derivative | 21,811 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002975 · edgar.xml · derivative · entry 8 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,812 Underlying: Common Stock · 21,811 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Performance stock units convert to shares of TDOC common stock on a one-for-one basis. F7 · derivative.exercise_date: On February 26, 2020, the reporting person earned 65,435 performance stock units, vesting in three substantially equal annual installments beginning on March 4, 2020. The number of performance stock units earned has been increased by two due to a rounding error on the reporting person's Form 4 that was filed on February 28, 2020. F7 · derivative.expiration_date: On February 26, 2020, the reporting person earned 65,435 performance stock units, vesting in three substantially equal annual installments beginning on March 4, 2020. The number of performance stock units earned has been increased by two due to a rounding error on the reporting person's Form 4 that was filed on February 28, 2020. F7 · balance_after: On February 26, 2020, the reporting person earned 65,435 performance stock units, vesting in three substantially equal annual installments beginning on March 4, 2020. The number of performance stock units earned has been increased by two due to a rounding error on the reporting person's Form 4 that was filed on February 28, 2020. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:15 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 16,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002975 · edgar.xml · derivative · entry 7 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,778 Underlying: Common Stock · 16,777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. F6 · derivative.exercise_date: On March 4, 2019, the reporting person was granted 50,333 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On March 4, 2019, the reporting person was granted 50,333 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:15 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 21,811 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-002975 · edgar.xml · nonDerivative · entry 5 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Performance stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:15 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 16,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-002975 · edgar.xml · nonDerivative · entry 4 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:15 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 6,206 | $200.48 | $1,244,147.85 |
DisclosureSEC source: 0001179110-21-002975 · edgar.xml · nonDerivative · entry 3 GOREVIC JASON N · CIK 0001208500 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,928 F4 · shares: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock unit awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.